聚焦2026 版:已完成临床试验年报。Only the met/endo and oncology therapeutic areas saw growth, both in late-stage trials,with met/endo rising by 15% (148 to 170)and oncology rising by 13% (186 to 211). This increase in late-stage met/endo clinical trial activity can largely be attributed to the increase in GLP-1 trials.
聚焦2026 版:已完成临床试验年报。Only the met/endo and oncology therapeutic areas saw growth, both in late-stage trials,with met/endo rising by 15% (148 to 170)and oncology rising by 13% (186 to 211). This increase in late-stage met/endo clinical trial activity can largely be attributed to the increase in GLP-1 trials.
聚焦2026 版:已完成临床试验年报。Only the met/endo and oncology therapeutic areas saw growth, both in late-stage trials,with met/endo rising by 15% (148 to 170)and oncology rising by 13% (186 to 211). This increase in late-stage met/endo clinical trial activity can largely be attributed to the increase in GLP-1 trials.
覆盖 2026 年,全文共 38 页。
本报告为付费报告,可在资料宝站内下单后获取完整内容。
重点分析了临床、已完成临床试验年报等议题。